# Damora Therapeutics Inc. (DMRA)

Source: https://www.quantisnow.com/company/DMRA
Generated: 2026-11-08T14:12:53.108Z

- Ticker: DMRA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2020
- SEC CIK: 0001800315

## Latest DMRA news and filings

- 2026-11-05 21:01 UTC [Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/damora-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6775891)
- 2026-11-04 21:06 UTC [Earnings] [Damora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights](https://www.quantisnow.com/insight/damora-therapeutics-reports-third-quarter-2026-financial-results-and-recent-6772417)
- 2026-11-04 21:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Damora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-damora-therapeutics-inc-6772168)
- 2026-11-04 14:00 UTC [Damora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at the American Society of Hematology (ASH) 2026 Annual Meeting](https://www.quantisnow.com/insight/damora-therapeutics-to-present-new-preclinical-data-highlighting-potentially-best-in-class-6771631)
- 2026-10-02 11:59 UTC [Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/damora-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6733471)
- 2026-09-28 11:00 UTC [Insider Buy] [Director, President and CEO Jarrett Jennifer bought $252,875 worth of Ordinary Shares (12,500 units at $20.23), increasing direct ownership by 2% to 512,500 units (SEC Form 4)](https://www.quantisnow.com/insight/director-president-and-ceo-jarrett-jennifer-bought-252875-worth-of-6727057)
- 2026-09-03 12:00 UTC [Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/damora-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6704315)
- 2026-08-13 21:00 UTC [SEC Form 4] [SEC Form 4 filed by Director Cheng Andrew](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-cheng-andrew-6681146)
- 2026-08-13 20:55 UTC [SEC Form 3] [SEC Form 3 filed by new insider Cheng Andrew](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-cheng-andrew-6681100)
- 2026-08-13 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Damora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-damora-therapeutics-inc-6678991)
- 2026-08-10 21:28 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Damora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-damora-therapeutics-inc-6674384)
- 2026-08-10 21:26 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Damora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-damora-therapeutics-inc-6674378)
- 2026-08-10 21:24 UTC [SEC Form POSASR filed by Damora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-posasr-filed-by-damora-therapeutics-inc-6674362)
- 2026-08-10 21:22 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Damora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-damora-therapeutics-inc-6674353)
- 2026-08-10 21:20 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Damora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-damora-therapeutics-inc-6674334)
- 2026-08-10 21:18 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Damora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-damora-therapeutics-inc-6674322)
- 2026-08-10 21:16 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Damora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-damora-therapeutics-inc-6674310)
- 2026-08-10 21:14 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Damora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-damora-therapeutics-inc-6674299)
- 2026-08-10 21:12 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Damora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-damora-therapeutics-inc-6674290)
- 2026-08-10 20:45 UTC [SEC Form POS AM filed by Damora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-damora-therapeutics-inc-6674136)
- 2026-08-10 20:14 UTC [Amendment: SEC Form 8-A12B/A filed by Damora Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-8-a12ba-filed-by-damora-therapeutics-inc-6673771)
- 2026-08-10 20:05 UTC [Leadership Update] [Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights](https://www.quantisnow.com/insight/damora-therapeutics-reports-second-quarter-2026-financial-results-and-recent-6673516)
- 2026-08-10 20:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Damora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-damora-therapeutics-inc-6673467)
- 2026-08-05 12:00 UTC [Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis](https://www.quantisnow.com/insight/damora-therapeutics-initiates-phase-11b-clarity-101-clinical-trial-of-dmr-001-6664032)
- 2026-08-03 20:01 UTC [Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/damora-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6659509)
- 2026-07-27 12:34 UTC [Analyst Coverage Initiated] [Jefferies initiated coverage on Damora Therapeutics with a new price target](https://www.quantisnow.com/insight/jefferies-initiated-coverage-on-damora-therapeutics-with-a-new-price-6649182)
- 2026-07-20 20:00 UTC [SEC Form 8-K] [Damora Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/damora-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6642358)
- 2026-07-17 12:00 UTC [Damora Announces Redomestication from Delaware to Cayman Islands](https://www.quantisnow.com/insight/damora-announces-redomestication-from-delaware-to-cayman-islands-6640523)
- 2026-07-08 00:00 UTC [SEC Form 4] [General Counsel Winslow Garrett converted options into 680 shares and sold $7,345 worth of shares (245 units at $29.98), increasing direct ownership by 23% to 2,289 units (SEC Form 4) (for withholding tax)](https://www.quantisnow.com/insight/general-counsel-winslow-garrett-converted-options-into-680-shares-and-6630660)
- 2026-07-01 20:01 UTC [Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/damora-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6622714)
- 2026-06-17 20:00 UTC [SEC Form 8-K] [Damora Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/damora-therapeutics-inc-filed-sec-form-8-k-submission-of-matters-6606453)
- 2026-06-11 12:10 UTC [Analyst Coverage Initiated] [H.C. Wainwright initiated coverage on Damora Therapeutics with a new price target](https://www.quantisnow.com/insight/hc-wainwright-initiated-coverage-on-damora-therapeutics-with-a-new-6598299)
- 2026-06-08 12:04 UTC [Analyst Coverage Initiated] [TD Cowen initiated coverage on Damora Therapeutics](https://www.quantisnow.com/insight/td-cowen-initiated-coverage-on-damora-therapeutics-6592650)
- 2026-06-01 12:00 UTC [Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/damora-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6580703)
- 2026-05-28 12:55 UTC [Analyst Coverage Initiated] [Wedbush initiated coverage on Damora Therapeutics with a new price target](https://www.quantisnow.com/insight/wedbush-initiated-coverage-on-damora-therapeutics-with-a-new-price-6576396)
- 2026-05-15 12:16 UTC [SEC Form SCHEDULE 13G filed by Damora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-damora-therapeutics-inc-6555858)
- 2026-05-12 20:05 UTC [Leadership Update] [Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights](https://www.quantisnow.com/insight/damora-therapeutics-reports-first-quarter-2026-financial-results-and-recent-6547865)
- 2026-05-12 20:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Damora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-damora-therapeutics-inc-6547740)
- 2026-05-08 21:00 UTC [SEC Form 3] [SEC Form 3 filed by new insider Burkavage Brian](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-burkavage-brian-6542789)
- 2026-05-04 20:00 UTC [SEC Form 8-K] [Damora Therapeutics Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/damora-therapeutics-inc-filed-sec-form-8-k-leadership-update-6528737)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/DMRA
- Earnings history: https://www.quantisnow.com/earnings/DMRA
- Dividend history: https://www.quantisnow.com/dividends/DMRA
- Insider transactions: https://www.quantisnow.com/insiders/DMRA
- Options chain: https://www.quantisnow.com/options/DMRA
- SEC 8-K filings only: https://www.quantisnow.com/company/DMRA/8-k
- RSS and alerts for DMRA: https://www.quantisnow.com/docs/rss-feeds.md